Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- VRCA
- Price
- 0.55
- Stock movement up
- +0.07 (14.24%)
- Company name
- Verrica Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 50.07M
- Ent value
- 94.09M
- Price/Sales
- 5.44
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 0.97%
- 1 year return
- -92.18%
- 3 year return
- -60.25%
- 5 year return
- -44.94%
- 10 year return
- -
Last updated: 2025-04-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
VRCA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 5.44 |
| Price to Book | - |
| EV to Sales | 10.22 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 90.56M |
| EPS (TTM) | -1.82 |
| FCF per share (TTM) | -1.28 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 9.21M |
| Gross profit (TTM) | 6.71M |
| Operating income (TTM) | -75.11M |
| Net income (TTM) | -84.99M |
| EPS (TTM) | -1.82 |
| EPS (1y forward) | -0.67 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 72.90% |
| Operating margin (TTM) | -815.50% |
| Profit margin (TTM) | -922.81% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 22.96M |
| Net receivables | 84.00K |
| Total current assets | 28.19M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 5.47M |
| Total assets | 32.93M |
| Accounts payable | 966.00K |
| Short/Current long term debt | 47.11M |
| Total current liabilities | 21.03M |
| Total liabilities | 66.98M |
| Shareholder's equity | -34.05M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -59.59M |
| Capital expenditures (TTM) | 254.00K |
| Free cash flow (TTM) | -59.85M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -258.12% |
| Return on Invested Capital | -734.20% |
| Cash Return on Invested Capital | -517.00% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.49 |
| Daily high | 0.58 |
| Daily low | 0.48 |
| Daily Volume | 497K |
| All-time high | 20.34 |
| 1y analyst estimate | 6.33 |
| Beta | 1.46 |
| EPS (TTM) | -1.82 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 12 May 2025 |
Downside potential
Loading...
Downside potential data
| VRCA | S&P500 | |
| Current price drop from All-time high | -97.28% | -12.04% |
| Highest price drop | -97.93% | -56.47% |
| Date of highest drop | 3 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -58.55% | -11.07% |
| Avg time to new high | 429 days | 12 days |
| Max time to new high | 1711 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
50.07M
Marketcap category
Small-cap
Description
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Employees
100
Website
Investor relations
-
SEC filings
CEO
Ted White
Country
USA
City
West Chester
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page